|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400093392 |
|
最近更新日期: Date of Last Refreshed on: |
2024-12-03 18:04:02 |
|
注册时间: Date of Registration: |
2024-12-03 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
大鲵黏蛋白生物黏合剂促皮肤伤口愈合的效果研究 |
|
Public title: |
A Bioadhesive Derived from Mucin of Andrias davidianus for Wound Healing |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
大鲵黏蛋白生物黏合剂促皮肤伤口愈合的效果研究 |
|
Scientific title: |
A Bioadhesive Derived from Mucin of Andrias davidianus for Wound Healing |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘世林 |
研究负责人: |
张曦木 |
|
Applicant: |
Shilin Liu |
Study leader: |
Ximu Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 182 9040 7052 |
研究负责人电话:
Study leader's |
+86 132 7269 1571 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
724568127@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
zhangximu@hospital.cqmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
重庆医科大学附属口腔医院 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
重庆市渝北区松石北路426号 |
研究负责人通讯地址: |
重庆市渝北区松石北路426号 |
|
Applicant address: |
No. 426, Songshi North Road, Yubei District, Chongqing |
Study leader's address: |
Thanks |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆医科大学附属口腔医院 |
||
|
Applicant's institution: |
The Affiliated Stomatological Hospital of Chongqing Medical University |
||
|
研究负责人所在单位: |
重庆医科大学附属口腔医院 |
||
|
Affiliation of the Leader: |
The Affiliated Stomatological Hospital of Chongqing Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024年伦审(131)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆医科大学附属口腔医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Affiliated Stomatological Hospital of Chongqing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-31 00:00:00 | ||
|
伦理委员会联系人: |
李海东 |
||
|
Contact Name of the ethic committee: |
Haidong Li |
||
|
伦理委员会联系地址: |
重庆市渝北区松石北路426号 |
||
|
Contact Address of the ethic committee: |
No. 426, Songshi North Road, Yubei District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 8860 2305 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
重庆医科大学附属口腔医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Affiliated Stomatological Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝北区松石北路426号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 426, Songshi North Road, Yubei District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重庆市科学技术局 |
||||||||||||||||||||||
|
Source(s) of funding: |
Chongqing Municipal Bureau of Science and Technology |
||||||||||||||||||||||
|
研究疾病: |
皮肤伤口愈合 |
||||||||||||||||||||||
|
Target disease: |
Wound healing |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
本研究的目的是研究大鲵黏蛋白生物黏合剂体内皮肤伤口愈合的效果,并收集试验数据,进行不同层级的学术交流。所得数据并不用于医疗器械注册。 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study was to study the effect of giant salamander mucin bioadhesive on skin wound healing in vivo, and to collect experimental data for academic exchanges at different levels. The data obtained is not used for the registration of medical devices. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
受试者纳入标准: (1)年龄:18-50周岁; (2)性别:男女不限; (3)健康状况:参与者没有患有任何严重的慢性或急性疾病,包括但不限于心脏病、糖尿病、高血压等。此外,参与者不应有任何精神疾病或药物滥用问题。 (4)体质指数(BMI):BMI应在一定范围内,通常在18.5-24.9之间。 (5)生活习惯:参与者应没有吸烟、饮酒或使用非法药物的习惯。 (6)同意并签署知情同意书:所有参与者都须同意参加研究并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
Subject inclusion Criteria: (1) Age: 18-50 years old; (2) Gender: either male or female; (3) Health status: Participants did not have any serious chronic or acute illness, including but not limited to heart disease, diabetes mellitus, high blood pressure, etc. Furthermore, participants should not have any mental illness or substance abuse problems. (4) Physical fitness index (BMI): BMI should be within a certain range, usually between 18.5-24.9. (5) Living habits: Participants should not be in the habit of smoking, drinking alcohol, or using illicit drugs. Consent and signed the informed consent: (6) All participants agreed to participate in the study and sign the informed consent. |
||||||||||||||||||||||
|
排除标准: |
受试者排除标准: (1)局麻药物过敏; (2)过敏体质(对两种以上药物、食物、花粉过敏); (3)有肝、肾、造血系统等严重原发性疾病者,或肝功能异常,AST、ALT大于正常值1.5/2倍,肌酐大于正常值上限者;精神病患者; (4)患有严重消化道疾病的患者,如消化道溃疡、严重呕吐、腹泻、胃排空延迟、 肠梗阻等(有其它影响药物吸收、分布、消除等因素者); (5)肾功能不全患者(血肌酐、尿素氮超过正常值范围的1.2倍); (6)已知重大的活动性感染,或研究者判断存在重大的血液、肾脏、代谢、胃肠或内分泌功能紊乱; (7)有免疫缺陷病史,包括HIV检测阳性或患有其它获得性、先天性免疫缺陷疾病,或有器官移植史者; (8)妊娠期、哺乳期妇女或有妊娠意向妇女;受试者妊娠或哺乳,或计划在治疗期间和/或治疗结束后15周内妊娠或哺乳; (9)近三个月内参加其它临床试验者; (10)怀疑或确有吸毒者;目前有酗酒、吸烟(每日≥5根)等不良嗜好。a.酗酒者即每周饮酒超过14单位酒精(1单位=360 mL啤酒或45 mL酒精量为40%的烈酒或150 mL葡萄酒); (11)过去的10年内有恶性肿瘤(非黑色素皮肤癌、宫颈原位癌、乳房原位导管癌或1期前列腺癌除外); (12)有滥用药物、毒品或酗酒史者; (13)给药前4周内进行过大手术; (14)肿瘤患者,预期生命 < 6个月; (15)主要脏器外科手术后未满6周患者,手术伤口愈合不良患者; (16)治疗前3个月内接种过活疫苗者; (17)研究者认为不适合入选的其他情况; |
||||||||||||||||||||||
|
Exclusion criteria: |
Subject Exclusion Criteria for: 1. Local anesthesia drug allergy; 2. Allergy constitution (allergic to more than two drugs, food, pollen); 3. Patients with severe primary diseases such as liver, kidney and hematopoietic system, or abnormal liver function, AST and ALT are 1.5 / 2 times greater than the normal value, and creatinine is greater than the upper limit of the normal value; patients with mental illness; 4. Patients with severe digestive tract diseases, such as gastrointestinal ulcer, severe vomiting, diarrhea, delayed gastric emptying, intestinal obstruction, etc. (with other factors affecting the absorption, distribution and elimination of drugs); 5. Patients with renal insufficiency (blood creatinine, urea nitrogen over 1.2 times the normal range); 6. Known major active infection, or major blood, renal, metabolic, gastrointestinal, or endocrine disorders as judged by the investigator; 7. A history of immunodeficiency, including a positive HIV test or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation; 8. Women during pregnancy, lactation, or women with pregnancy intention; the subject is pregnant or breastfeeding, or planned to become pregnant or lactating during and / or within 15 weeks after completion of treatment; 9. Participants in other clinical trials in the past three months; 10.Suspected or actual drug users; current adverse habits such as alcohol and smoking (5 per day). A. Alcoholics drink more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of alcohol or 150 mL of alcohol); 11. In the past 10 years, there was a malignancy (except for non-melanin skin cancer, cervical cancer in situ, ductal carcinoma in situ of the breast, or stage 1 prostate cancer); 12. A history of drug abuse, drugs, or alcohol abuse; 13. Major surgery within 4 weeks prior to drug administration; 14. Tumor patients with an expected life of <6 months; 15. Patients with less than 6 weeks after the surgery of major organs, patients with poor surgical wound healing; 16. Those who have been vaccinated within 3 months before treatment; 17. Other circumstances considered unsuitable by the investigator for inclusion; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-12-03 00:00:00至 To 2025-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-12-03 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
none |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
none |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
无 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
none |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |